logo
AI Icon𝛼SK or Search
ENTITY
Sosei Group

Sosei Group (4565 JP)

52
Analysis
Health Care • Japan
Sosei Group Corporation is a holding company which was established through reorganization. The Group companies are biopharmaceutical companies specializing in drug development. Sosei Group enters into license agreements primarily with US, EU, and Japanese companies to market the licensed drugs in Japan and find alternative usage on such drugs.
more
bullish•Sosei Group
•08 Aug 2026 16:00•Issuer-paid

Sosei Group (4565 JP): 1H FY12/26 flash update

Revenue increased to JPY18.9bn (+25.3% YoY), driven by milestone achievements and strong sales of Pivlaz® and Quviviq®. R&D expenses decreased...

Logo
Shared Research
112 Views
Share
bullish•Sosei Group
•07 May 2026 11:00•Issuer-paid

Sosei Group (4565 JP): Q1 FY12/26 flash update

Revenue increased to JPY11.3bn (+69.4% YoY), driven by milestone achievements, while R&D expenses decreased by 20.5% YoY. Core operating...

Logo
Shared Research
157 Views
Share
bullish•Sosei Group
•09 Apr 2026 07:49

Primer: Sosei Group (4565 JP) - Apr 2026

Sosei Group, which has rebranded to Nxera Pharma as of April 2024, is a technology-driven biopharmaceutical company with a world-leading...

Logo
Share
bullish•Thematic (Sector/Industry)
•06 Sep 2026 08:30

APAC Healthcare Weekly (Sept 6) – Simcere, Hutchmed, Akeso, Daiichi Sankyo, Alteogen, Pharmaessentia

Simcere and Hutchmend inked outlicensing deals with Roche and GSK, respectively. Akeso’s ivonescimab extends lives vs Keytruda. Alteogen inked...

Logo
Tina Banerjee
103 Views
Share
bullish•Thematic (Sector/Industry)
•30 Aug 2026 08:30

APAC Healthcare Weekly (August 30)– CSPC Pharma, Akeso, Takeda, Astellas, Hanmi Pharm, SK Biopharma

CSPC and Akeso announced positive results from their respective Phase 3 trials for cancer drug candidates. Takeda got FDA approval for blood cancer...

Logo
Tina Banerjee
103 Views
Share

Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.70.4

x